アカデミアによる臓器横断的ながん治療情報サイト

学会速報レポート

  1. Home
  2. Congress Report
  3. ASCO-GI 2020

海外学会で発表されたホットでタイムリーな演題を専門医が厳選。レポートとコメントを掲載しています。

ASCO-GI 2020

2020年1月23日～25日にサンフランシスコで開催の消化器癌シンポジウム2020 より注目演題のレポートを掲載しています。
※取り上げる演題は予告なく変更される場合がございますので、予めご了承ください。

Abstract: 133 大腸癌

  • 2020年03月06日

Pembrolizuamb in Patients with Metastatic Colorectal Cancer with High Tumor Mutational Burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR)Study.
First Author: Eyal Meiri, et al.

Abstract: 638 肝胆膵癌

  • 2020年03月06日

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma.
First Author: Margaret A. Tempero, et al.

Abstract: 278 胃癌

  • 2020年03月04日

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
First Author: Moehler, et al.

Abstract 1: 大腸癌

  • 2020年03月04日

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.
First Author: Aurelien Marabelle, et al.

Abstract: 476 肝胆膵癌

  • 2020年02月14日

Patient-reported outcomes (PROs) from the Phase Ⅲ IMbrave150 trial of atezolizumab (atezo) + Bevacizumab (bev) vs Sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
First Author: Peter R. Galle, et al.

Abstract: 5 大腸癌

  • 2020年02月12日

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
First Author: Yoshiaki Nakamura et al.

Abstract: 281 食道癌

  • 2020年02月06日

A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study.
First Author: Maarten C.C.M. Hulshof, et al.

Abstract: 100 大腸癌

  • 2020年02月06日

VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.
First Author: Takeshi Kato, et al.

Abstract: 478 肝胆膵癌

  • 2020年02月06日

Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau, et al.

Abstract: 7 大腸癌

  • 2020年02月06日

A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS).
First Author: Yukihide Kanemitsu et al.

Abstract: 374 胃癌

  • 2020年01月31日

An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
First Author: Akihito Kawazoe, et al.

Abstract: 383 胃癌

  • 2019年01月31日

A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.
First Author: Li-Tzong Chen, et al.

Abstract: 178 大腸癌

  • 2020年01月28日

Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer (mCRC): Preliminary results from GI-SCREEN CRC-Ukit study.
First Author: Taniguchi, et al.